![Ellen Feigal](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Ellen Feigal
Direttore/Membro del Consiglio presso
XENCOR, INC.
Patrimonio netto: 65 304 $ in data 31/05/2026
Profilo
Ellen G.
Feigal currently works at Foundation For Cell & Gene Medicine, as Director, Prescient Therapeutics Ltd., as Non-Executive Director from 2023, NextCure, Inc., as Independent Director from 2021, Xencor, Inc., as Independent Director from 2018, and NDA Partners LLC, as Partner & Head-Biologics Practice from 2014.
Dr. Feigal also formerly worked at Amgen, Inc., as Executive Medical Director-Global Development from 2008 to 2011, The University of California, San Francisco, as Director, National Cancer Institute, as Deputy Director-Cancer Treatment Division, Critical Path Institute, as Director-Medical Devices & Imaging from 2006 to 2007, the University of California, as Director-American Course on Drug Development from 2006 to 2011, Translational Genomics Research Institute, as Vice President-Clinical Sciences from 2004 to 2007, INSYS Therapeutics, Inc., as Chief Medical Officer from 2007 to 2008, and California Institute for Regenerative Medicine, as Vice President-Research & Development from 2011 to 2014.
Dr. Feigal received her graduate degree from the University of California, Berkeley, doctorate degree from the University of California, Davis, undergraduate degree from the University of Minnesota, and doctorate degree from Stanford University School of Medicine.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
XENCOR, INC. 0,01% | 28/02/2026 | 5.497 ( 0,01% ) | 65 304 $ | 31/05/2026 |
NEXTCURE, INC. -.--% | 22/04/2026 | 0 ( -.--% ) | - $ | 31/05/2026 |
| 30/06/2025 | 0 ( -.--% ) | - $ | 31/05/2026 |
Posizioni attive di Ellen Feigal
| Società | Posizione | Inizio |
|---|---|---|
| NEXTCURE, INC. | Direttore/Membro del Consiglio | 01/10/2021 |
| PRESCIENT THERAPEUTICS LIMITED | Direttore/Membro del Consiglio | 15/05/2023 |
| XENCOR, INC. | Direttore/Membro del Consiglio | 01/11/2018 |
NDA Partners LLC
 NDA Partners LLC Miscellaneous Commercial ServicesCommercial Services Provides strategy consulting services | Corporate Officer/Principal | 01/12/2014 |
Foundation For Cell & Gene Medicine
 Foundation For Cell & Gene Medicine Foundation For Cell & Gene Medicine is an independent international nonprofit organization established in 2018 by the Alliance for Regenerative Medicine, dedicated to advancing ethical cell and gene therapies, tissue-engineered products, and regenerative medicine. The private company is located in the US. Its mission is to accelerate patient access to safe, effective, and potentially curative therapies by educating patients, caregivers, healthcare professionals, policymakers, and the public. The foundation conducts programs focused on education, health and economic impact analysis, and infrastructure development for the adoption of these treatments. Key initiatives include the State Rare Disease Education Initiative (STRIDE), which provides patient-centered, state-specific education to improve access to innovative therapies for rare diseases; the Health & Economic Impact (HEI) program, which develops frameworks and economic models to demonstrate the value of cell and gene therapies; and the Infrastructure Program, which addresses logistical and healthcare system needs for widespread therapy adoption. The foundation also offers educational resources, a standardized nomenclature project, and outreach efforts such as webinars, social media campaigns, toolkits, and conferences. Its leadership and steering committees include experts from various fields such as industry, patient advocacy, health economics, communications, public policy, manufacturing, and precision medicine. | Direttore/Membro del Consiglio | - |
Precedenti posizioni note di Ellen Feigal
| Società | Posizione | Fine |
|---|---|---|
California Institute for Regenerative Medicine
 California Institute for Regenerative Medicine General GovernmentGovernment Provides medical services | Direttore Tecnico/Scientifico/R&S | 01/12/2014 |
University of California
 University of California Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | 01/01/2011 |
| AMGEN INC. | Corporate Officer/Principal | 01/01/2011 |
| INSYS THERAPEUTICS, INC. | Direttore Tecnico/Scientifico/R&S | 01/01/2008 |
| ░░░░░░░░░░░░░ ░░░░░░░░ ░░░░░░░░ ░░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formazione di Ellen Feigal
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
63
Relazioni di 1° grado
17
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 17 |
|---|---|
Amgen, Inc.
 Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
Xencor, Inc.
 Xencor, Inc. BiotechnologyHealth Technology Develops therapeutics to treat autoimmune and allergic diseases, cancer and other conditions | Health Technology |
Prescient Therapeutics Ltd.
 Prescient Therapeutics Ltd. BiotechnologyHealth Technology Operates as a a clinical stage oncology company | Health Technology |
University of California, Berkeley
 University of California, Berkeley Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California, Davis
 University of California, Davis Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Minnesota
 University of Minnesota Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The University of California, San Francisco
 The University of California, San Francisco Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
National Cancer Institute
 National Cancer Institute Investment Trusts/Mutual FundsMiscellaneous Conducts research projects & awards grants for cancer research | Miscellaneous |
California Institute for Regenerative Medicine
California Institute for Regenerative Medicine General GovernmentGovernment Provides medical services | Government |
NDA Partners LLC
NDA Partners LLC Miscellaneous Commercial ServicesCommercial Services Provides strategy consulting services | Commercial Services |
Translational Genomics Research Institute
 Translational Genomics Research Institute Miscellaneous Commercial ServicesCommercial Services Operates as a cancer, neurological disorders and infectious disease medical research institute | Commercial Services |
Critical Path Institute
 Critical Path Institute Miscellaneous Commercial ServicesCommercial Services Provides medical drug and product development review process | Commercial Services |
INSYS Therapeutics, Inc.
 INSYS Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a specialty pharmaceutical company | Health Technology |
University of California
University of California Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Stanford University School of Medicine
 Stanford University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
NextCure, Inc.
 NextCure, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which discovers and develops novel immuno medicines to treat cancer & immune related diseases | Health Technology |
Foundation For Cell & Gene Medicine
Foundation For Cell & Gene Medicine Foundation For Cell & Gene Medicine is an independent international nonprofit organization established in 2018 by the Alliance for Regenerative Medicine, dedicated to advancing ethical cell and gene therapies, tissue-engineered products, and regenerative medicine. The private company is located in the US. Its mission is to accelerate patient access to safe, effective, and potentially curative therapies by educating patients, caregivers, healthcare professionals, policymakers, and the public. The foundation conducts programs focused on education, health and economic impact analysis, and infrastructure development for the adoption of these treatments. Key initiatives include the State Rare Disease Education Initiative (STRIDE), which provides patient-centered, state-specific education to improve access to innovative therapies for rare diseases; the Health & Economic Impact (HEI) program, which develops frameworks and economic models to demonstrate the value of cell and gene therapies; and the Infrastructure Program, which addresses logistical and healthcare system needs for widespread therapy adoption. The foundation also offers educational resources, a standardized nomenclature project, and outreach efforts such as webinars, social media campaigns, toolkits, and conferences. Its leadership and steering committees include experts from various fields such as industry, patient advocacy, health economics, communications, public policy, manufacturing, and precision medicine. |
